Role of miRNAs in regulating responses to radiotherapy in human breast cancer

References

• Ades F, Tryfonidis K, Zardavas D. 2017. The past and future of breast cancer treatment-from the papyrus to individualised treatment approaches. ecancermedicalscience. 11:746.
   PubMed Web of Science ®Google Scholar
• Al-Assar O, Muschel RJ, Mantoni TS, McKenna WG, Brunner TB. 2009. Radiation response of cancer stem-like cells from established human cell lines after sorting for surface markers. Int J Radiat Oncol Biol Phys. 75(4):1216–1225.
   PubMed Web of Science ®Google Scholar
• Al-Thoubaity FK. 2020. Molecular classification of breast cancer: a retrospective cohort study. Ann Med Surg. 49:44–48.
   PubMed Web of Science ®Google Scholar
• Anastasov N, Höfig I, Vasconcellos IG, Rappl K, Braselmann H, Ludyga N, Auer G, Aubele M, Atkinson MJ. 2012. Radiation resistance due to high expression of miR-21 and G2/M checkpoint arrest in breast cancer cells. Radiat Oncol. 7(206):206–212.
   PubMedGoogle Scholar
• Aratani S, Tagawa M, Nagasa S, Sakai Y, Akira S, Tsuruoka S. 2018. Radiation-induced premature cellular senescence involved in glomerular diseases in rats. Sci Rep. 8(1):16812.
   PubMedGoogle Scholar
• Balbous A, Cortes U, Guilloteau K, Rivet P, Pinel B, Duchesne M, Godet J, Boissonnade O, Wager M, Bensadoun RJ, et al. 2016. A radiosensitizing effect of RAD51 inhibition in glioblastoma stem-like cells. BMC Cancer. 16:604.
   PubMed Web of Science ®Google Scholar
• Baskar R, Dai J, Wenlong N, Yeo R, Yeoh K-W. 2014. Biological response of cancer cells to radiation treatment. Front Mol Biosci. 1:24.
   PubMed Web of Science ®Google Scholar
• Becker S. 2015. A historic and scientific review of breast cancer: the next global healthcare challenge. Int J Gynecol Obstetr. 131(Sup 1):S36–S39.
   PubMedGoogle Scholar
• Bian L, Meng Y, Zhang M, Guo Z, Liu F, Zhang W, Ke X, Su Y, Wang M, Yao Y, et al. 2020. ATM expression is elevated in established radiation-resistant breast cancer cells and improves DNA repair efficiency. Int J Biol Sci. 16(7):1096–1106.
   PubMed Web of Science ®Google Scholar
• Blaisdell JO, Harrison L, Wallace SS. 2001. Base excision repair processing of radiation-induced clustered DNA lesions. Radiat Prot Dosimetry. 97(1):25–31.
   PubMed Web of Science ®Google Scholar
• Borrego-Soto G, Ortiz-López R, Rojas-Martínez A. 2015. Ionizing radiation-induced DNA injury and damage detection in patients with breast cancer. Genet Mol Biol. 38 (4):420–432.
   PubMed Web of Science ®Google Scholar
• Brody T. 2011. Clinical trials: study design, endpoints and biomarkers, drug safety, and FDA and ICH guidelines.
   Google Scholar
• Bylicky MA, Mueller GP, Day RM. 2019. Radiation resistance of normal human astrocytes: the role of non-homologous end joining DNA repair activity. J Radiat Res. 60(1):37–50.
   PubMed Web of Science ®Google Scholar
• Cao X, Wen P, Fu Y, Gao Y, Qi X, Chen B, Tao Y, Wu L, Xu A, Lu H, et al. 2019. Radiation induces apoptosis primarily through the intrinsic pathway in mammalian cells. Cell Signal. 62:109337.
   PubMed Web of Science ®Google Scholar
• Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, Zackrisson S, Senkus E. 2019. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 30(8):1194–1220.
   Google Scholar
• Carlson RW. 2005. The history and mechanism of action of Fulvestrant. Clin Breast Cancer. 6(1):S5–S8.
   PubMedGoogle Scholar
• Castedo M, Perfettini J, Roumier T, Andreau K, Medema R, Kroemer G. 2004. Cell death by mitotic catastrophe : a molecular definition. Oncogene. 23(16):2825–2837.
   PubMed Web of Science ®Google Scholar
• Chai Y, Yang X, Li Y, Qu Q. 2017. MicroRNA-185 overexpression sensitizes breast cancer cells to ionizing radiation: a potential therapeutic role in breast cancer. Int J Clin Exp Path. 10(1):274–281.
   Web of Science ®Google Scholar
• Chargari C, Deutsch E, Blanchard P, Gouy S, Martelli H, Guérin F, Dumas I, Bossi A, Morice P, Viswanathan AN, et al. 2019. Brachytherapy: an overview for clinicians. CA Cancer J Clin. 69(5):386–401.
   PubMed Web of Science ®Google Scholar
• Dasari S, Tchounwou PB. 2014. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 740:364–378.
   PubMed Web of Science ®Google Scholar
• Deckbar D, Jeggo PA, Löbrich M. 2011. Understanding the limitations of radiation-induced cell cycle checkpoints. Crit Rev Biochem Mol Biol. 46(4):271–283.
   PubMed Web of Science ®Google Scholar
• Ditsch N, Untch M, Thill M, Müller V, Janni W, Albert US, Bauerfeind I, Blohmer J, Budach W, Dall P, et al. 2019. AGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2019. Breast Care. 14(4):224–245.
   PubMed Web of Science ®Google Scholar
• Dodson H, Wheatley SP, Morrison CG. 2007. Involvement of centrosome amplification in radiation-induced mitotic catastrophe. Cell Cycle. 6(3):364–370.
   PubMed Web of Science ®Google Scholar
• Drohat AC, Coey CT. 2016. Role of base excision “repair” enzymes in erasing epigenetic marks from DNA. Chem Rev. 116(20):12711–12729.
   PubMed Web of Science ®Google Scholar
• Egeland NG, Lunde S, Jonsdottir K, Lende TH, Cronin-Fenton D, Gilje B, Janssen EAM, Søiland H. 2015. The role of microRNAs as predictors of response to tamoxifen treatment in breast cancer patients. Int J Mol Sci. 16(10):24243–24275.
   PubMed Web of Science ®Google Scholar
• Eriksson D, Stigbrand T. 2010. Radiation-induced cell death mechanisms. Tumour Biol. 31(4):363–372.
   PubMedGoogle Scholar
• Fragomeni SM, Sciallis A, Jeruss JS. 2018. Molecular subtypes and local-regional control of breast cancer. Surg Oncol Clin N Am. 27(1):95–120.
   PubMed Web of Science ®Google Scholar
• Fu Y, Xiong J. 2016. MicroRNA-124 enhances response to radiotherapy in human epidermal growth factor receptor 2-positive breast cancer cells by targeting signal transducer and activator of transcription 3. Croat Med J. 57(5):457–464.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. 2015. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 28(6):690–714.
   PubMed Web of Science ®Google Scholar
• Gampenrieder SP, Rinnerthaler G, Greil R. 2013. Neoadjuvant chemotherapy and targeted therapy in breast cancer: past, present, and future. J Oncol. 2013:732047.
   PubMedGoogle Scholar
• Gasparini P, Lovat F, Fassan M, Casadei L, Cascione L, Jacob NK, Carasi S, Palmieri D, Costinean S, Shapiro CL, et al. 2014. Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation. Proc Natl Acad Sci USA. 111(12):4536–4541.
   PubMed Web of Science ®Google Scholar
• Gogineni VR, Nalla AK, Gupta R, Dinh DH, Klopfenstein JD, Rao JS. 2011. Chk2-mediated G2/M cell cycle arrest maintains radiation resistance in malignant meningioma cells. Cancer Lett. 313(1):64–75.
   PubMed Web of Science ®Google Scholar
• Gol TM, Rodemann HP, Dittmann K. 2019. Depletion of Akt1 and Akt2 impairs the repair of radiation-induced DNA double strand breaks via homologous recombination. Int J Mol Sci. 20(24):6316.
   Web of Science ®Google Scholar
• Grinan-Lison C, Olivares-Urbano AM, Jimenez G, Lopez-Ruiz E, Val C, del Morata-Tarifa C, Entrena JM, Gonzalez-Ramirez AR, Boulaiz H, Herrera MZ, et al. 2020. miRNAs as radio-response biomarkers for breast cancer stem cells. Mol Oncol. 14(3):556–570.
   PubMed Web of Science ®Google Scholar
• Guerra Liberal FDC, O'Sullivan JM, McMahon SJ, Prise KM. 2020. Targeted alpha therapy: current clinical applications. Cancer Biother Radiopharm. 35(6):404–417.
   PubMed Web of Science ®Google Scholar
• Heidari M, Shahbazi S, Ghodusi M. 2015. Evaluation of body esteem and mental health in patients with breast cancer after mastectomy. J Midlife Health. 6(4):173–177.
   PubMedGoogle Scholar
• Hsu JC, Lu CY. 2016. Longitudinal trends in use and costs of targeted therapies for common cancers in Taiwan: a retrospective observational study. BMJ Open. 6(6):e011322.
   PubMed Web of Science ®Google Scholar
• Hu WZ, Tan CL, He YJ, Zhang GQ, Xu Y, Tang JH. 2018. Functional miRNAs in breast cancer drug resistance. Onco Targets Ther. 11:1529–1541.
   PubMed Web of Science ®Google Scholar
• Hu X, Ding D, Zhang J, Cui J. 2019. Knockdown of lncRNA HOTAIR sensitizes breast cancer cells to ionizing radiation through activating miR-218. Bioscience Reports. 39(4):BSR20181038.
   PubMed Web of Science ®Google Scholar
• Huang L, Liao L, Wan Y, Cheng A, Li M, Chen S, Li M, Tan X, Zeng G. 2016. Downregulation of annexin A1 is correlated with radioresistance in nasopharyngeal carcinoma. Oncol Lett. 12(6):5229–5234.
   PubMed Web of Science ®Google Scholar
• Huang X, Taeb S, Jahangiri S, Emmenegger U, Tran E, Bruce J, Mesci A, Korpela E, Vesprini D, Wong CS, et al. 2013. miRNA-95 mediates radioresistance in tumors by targeting the sphingolipid phosphatase SGPP1. Cancer Res. 73(23):6972–6986.
   PubMed Web of Science ®Google Scholar
• Huang X, Taeb S, Jahangiri S, Korpela E, Cadonic I, Yu N, Krylov SN, Fokas E, Boutros PC, Liu SK. 2015. miR-620 promotes tumor radioresistance by targeting 15-hydroxyprostaglandin dehydrogenase (HPGD). Oncotarget. 6(26):22439–22451.
   PubMedGoogle Scholar
• Jiang W, Jin G, Cai F, Chen X, Cao N, Zhang X, Liu J, Chen F, Wang F, Dong W, et al. 2019. Extracellular signal-regulated kinase 5 increases radioresistance of lung cancer cells by enhancing the DNA damage response. Exp Mol Med. 51(2):1–20.
   Web of Science ®Google Scholar
• Johnston SJ, Cheung K-L. 2018. Endocrine therapy for breast cancer: a model of hormonal manipulation. Oncol Ther. 6(2):141–156.
   PubMed Web of Science ®Google Scholar
• Kato M, Paranjape T, Müller RU, Ullrich R, Nallur S, Gillespie E, Keane K, Esquela-Kerscher A, Weidhaas JB, Slack FJ. 2009. The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells. Oncogene. 28(25):2419–2424.
   PubMed Web of Science ®Google Scholar
• Kawamura K, Qi F, Kobayashi J. 2018. Potential relationship between the biological effects of low-dose irradiation and mitochondrial ROS production. J Radiat Res. 59(suppl_2):ii91–ii97.
   PubMedGoogle Scholar
• Krause M, Dubrovska A, Linge A, Baumann M. 2017. Cancer stem cells: radioresistance, prediction of radiotherapy outcome and specific targets for combined treatments. Adv Drug Deliv Rev. 109:63–73.
   PubMed Web of Science ®Google Scholar
• Lagadec C, Vlashi E, Della Donna L, Dekmezian C, Pajonk F. 2012. Radiation-induced reprogramming of breast cancer cells. Stem Cells. 30(5):833–844.
   PubMed Web of Science ®Google Scholar
• Lai Y, Chen Y, Lin Y, Ye L. 2018. Down-regulation of LncRNA CCAT1 enhances radiosensitivity via regulating miR-148b in breast cancer. Cell Biol Int. 42(2):227–236.
   PubMed Web of Science ®Google Scholar
• Lee HC, Her N-G, Kang D, Jung SH, Shin J, Lee M, Bae IH, Kim YN, Park HJ, Ko YG, et al. 2017. Radiation-inducible miR-770-5p sensitizes tumors to radiation through direct targeting of PDZ-binding kinase. Cell Death Dis. 8(3):e2693.
   PubMedGoogle Scholar
• Lee KM, Choi EJ, Kim IA. 2011. microRNA-7 increases radiosensitivity of human cancer cells with activated EGFR-associated signaling. Radiother Oncol. 101(1):171–176.
   PubMed Web of Science ®Google Scholar
• Lehmann-Che J, Andre F, Desmedt C, Mazouni C, Giacchetti S, Turpin E, Espie M, Plassa L-F, Marty M, Bertheau P, et al. 2010. Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers. Oncologist. 15(3):246–252.
   PubMed Web of Science ®Google Scholar
• Li L, Story M, Legerski RJ. 2001. Cellular responses to ionizing radiation damage. Int J Radiat Oncol. 49(4):1157–1162.
   PubMed Web of Science ®Google Scholar
• Li M, You L, Xue J, Lu Y. 2018. Ionizing radiation-induced cellular senescence in normal, non-transformed cells and the involved DNA damage response: a mini review. Front Pharmacol. 9:522.
   PubMed Web of Science ®Google Scholar
• Liang Z, Ahn J, Guo D, Votaw JR, Shim H. 2013. MicroRNA-302 replacement therapy sensitizes breast cancer cells to ionizing radiation. Pharm Res. 30(4):1008–1016.
   PubMed Web of Science ®Google Scholar
• Lieber MR. 2008. The mechanism of human nonhomologous DNA end joining. J Biol Chem. 283(1):1–5.
   PubMed Web of Science ®Google Scholar
• Lin J, Liu C, Gao F, Mitchel RE, Zhao L, Yang Y, Lei J, Cai J. 2013. miR-200c enhances radiosensitivity of human breast cancer cells. J Cell Biochem. 114(3):606–615.
   PubMed Web of Science ®Google Scholar
• Liu L, Zhu Y, Liu A, Feng Y, Chen Y. 2019. Long noncoding RNA LINC00511 involves in breast cancer recurrence and radioresistance by regulating STXBP4 expression via miR-185. Eur Rev Med Pharmacol Sci. 23(17):7457–7468.
   PubMed Web of Science ®Google Scholar
• Liu Y, Yang M, Luo J, Zhou H. 2020. Radiotherapy targeting cancer stem cells “awakens” them to induce tumour relapse and metastasis in oral cancer. Int J Oral Sci. 12(1):19.
   PubMed Web of Science ®Google Scholar
• Lou W, Liu J, Ding B, Xu L, Fan W. 2018. Identification of chemoresistance-associated miRNAs in breast cancer. Cancer Manag Res. 10:4747–4757.
   PubMed Web of Science ®Google Scholar
• Luo J, Chen J, He L. 2015. mir-129-5p attenuates irradiation-induced autophagy and decreases radioresistance of breast cancer cells by targeting HMGB1. Med Sci Monit. 21:4122–4129.
   PubMed Web of Science ®Google Scholar
• Luo M, Ding L, Li Q, Yao H. 2017. miR-668 enhances the radioresistance of human breast cancer cell by targeting IκBα. Breast Cancer. 24(5):673–682.
   PubMed Web of Science ®Google Scholar
• Manstein V, von Min Yang C, Richter D, Delis N, Vafaizadeh V, Groner B. 2013. Resistance of cancer cells to targeted therapies through the activation of compensating signaling loops. Curr Signal Transduct Ther. 8(3):193–202.
   PubMed Web of Science ®Google Scholar
• Mao Z, Bozzella M, Seluanov A, Gorbunova V. 2008. Comparison of nonhomologous end joining and homologous recombination in human cells. DNA Repair. 7(10):1765–1771.
   PubMed Web of Science ®Google Scholar
• Mariotto AB, Robin Yabroff K, Shao Y, Feuer EJ, Brown ML. 2011. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 103(2):117–128.
   PubMed Web of Science ®Google Scholar
• Mavragani IV, Nikitaki Z, Kalospyros SA, Georgakilas AG. 2019. Ionizing radiation and complex DNA damage: from prediction to detection challenges and biological significance. Cancers. 11(11):1789–1729.
   PubMed Web of Science ®Google Scholar
• Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Linden HM, et al. 2019. Overall survival with Fulvestrant plus Anastrozole in metastatic breast cancer. N Engl J Med. 380(13):1226–1234.
   PubMed Web of Science ®Google Scholar
• Mei Z, Su T, Ye J, Yang C, Zhang S, Xie C. 2015. The miR-15 family enhances the radiosensitivity of breast cancer cells by targeting G2 checkpoints. Radiat Res. 183(2):196–207.
   PubMed Web of Science ®Google Scholar
• Metheetrairut C, Adams BD, Nallur S, Weidhaas JB, Slack FJ. 2017. cel-mir-237 and its homologue, hsa-miR-125b, modulate the cellular response to ionizing radiation. Oncogene. 36(4):512–524.
   PubMed Web of Science ®Google Scholar
• Miller WR, Larionov AA. 2012. Understanding the mechanisms of aromatase inhibitor resistance. Breast Cancer Res. 14(1):201.
   PubMed Web of Science ®Google Scholar
• Moertl S, Mutschelknaus L, Heider T, Atkinson MJ. 2016. MicroRNAs as novel elements in personalized radiotherapy. Transl Cancer Res. 5(S6):S1262–S1269.
   Google Scholar
• Muluhngwi P, Klinge CM. 2015. Roles for miRNAs in endocrine resistance in breast cancer. Endocr Relat Cancer. 22(5):R279–R300.
   PubMed Web of Science ®Google Scholar
• Munagala R, Aqil F, Gupta R. 2011. Promising molecular targeted therapies in breast cancer. Indian J Pharmacol. 43(3):236–245.
   PubMed Web of Science ®Google Scholar
• Murugappan K, Saboo A, Kuo L, Ung O. 2018. Paradigm shift in the local treatment of breast cancer: mastectomy to breast conservation surgery. Gland Surg. 7(6):506–519.
   PubMed Web of Science ®Google Scholar
• Nounou MI, Elamrawy F, Ahmed N, Abdelraouf K, Goda S, Syed-Sha-Qhattal H. 2015. Breast cancer: conventional diagnosis and treatment modalities and recent patents and technologies. Breast Cancer. 9 (Suppl 2):17–34.
   PubMedGoogle Scholar
• Pajic M, Froio D, Daly S, Doculara L, Millar E, Graham PH, Drury A, Steinmann A, Bock CE, De Boulghourjian A, et al. 2018. miR-139-5p modulates radiotherapy resistance in breast cancer by repressing multiple gene networks of DNA repair and ROS defense. Cancer Res. 78(2):501–515.
   PubMed Web of Science ®Google Scholar
• Pascal JM. 2018. The comings and goings of PARP-1 in response to DNA damage. DNA Repair. 71:177–182.
   PubMed Web of Science ®Google Scholar
• Pearce A, Haas M, Viney R, Pearson S, Haywood P, Brown C, Ward R. 2017. Incidence and severity of self-reported chemotherapy side effects in routine care: a prospective cohort study. PLoS One. 12(10):e0184360.
   PubMed Web of Science ®Google Scholar
• Perez-Añorve IX, Gonzalez-De la Rosa CH, Soto-Reyes E, Beltran-Anaya FO, Del Moral-Hernandez O, Salgado-Albarran M, Angeles-Zaragoza O, Gonzalez-Barrios JA, Landero-Huerta DA, Chavez-Saldaña M, et al. 2019. New insights into radioresistance in breast cancer identify a dual function of miR-122 as a tumor suppressor and oncomiR. Mol Oncol. 13(5):1249–1267.
   PubMed Web of Science ®Google Scholar
• Poleszczuk J, Luddy K, Chen L, Lee JK, Harrison LB, Czerniecki BJ, Soliman H, Enderling H. 2017. Neoadjuvant radiotherapy of early-stage breast cancer and long-term disease-free survival. Breast Cancer Res. 19(1):75.
   PubMedGoogle Scholar
• Puhalla S, Bhattacharya S, Davidson NE. 2012. Hormonal therapy in breast cancer: a model disease for the personalization of cancer care. Mol Oncol. 6(2):222–236.
   PubMed Web of Science ®Google Scholar
• Ren Y, Fu F, Han J. 2015. MiR-27a modulates radiosensitivity of triple-negative breast cancer (TNBC) cells by targeting CDC27. Med Sci Monit. 21:1297–1303.
   PubMed Web of Science ®Google Scholar
• Rivankar S. 2014. An overview of doxorubicin formulations in cancer therapy. J Cancer Res Ther. 10(4):853–858.
   PubMed Web of Science ®Google Scholar
• Rossi L, Biagioni C, McCartney A, Migliaccio I, Curigliano G, Sanna G, Moretti E, Minisini AM, Cinieri S, Tondini C, et al. 2019. Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial. Breast Cancer Res. 21(1):71.
   PubMedGoogle Scholar
• Sautter-Bihl ML, Budach W, Dunst J, Feyer P, Haase W, Harms W, Sedlmayer F, Souchon R, Wenz F, Sauer R. 2007. DEGRO practical guidelines for radiotherapy of breast cancer I. Strahlenther Onkol. 183(12):661–666.
   PubMed Web of Science ®Google Scholar
• Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im S-A, Shaw Wright G, et al. 2018. Atezolizumab and Nab-Paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 379(22):2108–2121.
   PubMed Web of Science ®Google Scholar
• Schulz A, Meyer F, Dubrovska A, Borgmann K. 2019. Cancer stem cells and radioresistance: DNA repair and beyond. Cancers. 11(6):862.
   PubMed Web of Science ®Google Scholar
• Shi L, Tashiro S. 2018. Estimation of the effects of medical diagnostic radiation exposure based on DNA damage. J Radiat Res. 59(suppl_2):ii121–ii129.
   PubMedGoogle Scholar
• Sun L, Legood R, Dos-Santos-Silva I, Gaiha SM, Sadique Z. 2018. Global treatment costs of breast cancer by stage: a systematic review. PLoS One. 13(11):e0207993.
   PubMed Web of Science ®Google Scholar
• Sun Q, Liu T, Yuan Y, Guo Z, Xie G, Du S, Lin X, Xu Z, Liu M, Wang W, et al. 2015. MiR-200c inhibits autophagy and enhances radiosensitivity in breast cancer cells by targeting UBQLN1. Int J Cancer. 136(5):1003–1012.
   PubMed Web of Science ®Google Scholar
• Surova O, Zhivotovsky B. 2013. Various modes of cell death induced by DNA damage. Oncogene. 32(33):3789–3797.
   PubMed Web of Science ®Google Scholar
• Takesue T, Kawakubo H, Hayashida T, Tsutsui M, Miyao K, Fukuda K, Nakamura R, Takahashi T, Wada N, Takeuchi H, et al. 2017. Downregulation of cytochrome c oxidase 1 induced radioresistance in esophageal squamous cell carcinoma. Oncol Lett. 14(4):4220–4224.
   PubMed Web of Science ®Google Scholar
• Tan X, Li Z, Ren S, Rezaei K, Pan Q, Goldstein AT, Macri CJ, Cao D, Brem RF, Fu SW. 2019. Dynamically decreased miR-671-5p expression is associated with oncogenic transformation and radiochemoresistance in breast cancer. Breast Cancer Res. 21(1):89.
   PubMed Web of Science ®Google Scholar
• Tang L, Matsushita H, Jingu K. 2018. Controversial issues in radiotherapy after breast-conserving surgery for early breast cancer in older patients: a systematic review. J Radiat Res. 59(6):789–793.
   PubMed Web of Science ®Google Scholar
• Tang L, Wei F, Wu Y, He Y, Shi L, Xiong F, Gong Z, Guo C, Li X, Deng H, et al. 2018. Role of metabolism in cancer cell radioresistance and radiosensitization methods. J Exp Clin Cancer Res. 37(1):87.
   PubMedGoogle Scholar
• Taylor MA, Das BC, Ray SK. 2018. Targeting autophagy for combating chemoresistance and radioresistance in glioblastoma. Apoptosis. 23(11–12):563–575.
   PubMed Web of Science ®Google Scholar
• Thompson LH, Schild D. 2001. Homologous recombinational repair of DNA ensures mammalian chromosome stability. Mutat Res. 477(1–2):131–153.
   PubMed Web of Science ®Google Scholar
• Toufektchan E, Toledo F. 2018. The guardian of the genome revisited: p53 downregulates genes required for telomere maintenance, DNA repair, and centromere structure. Cancers. 10(5):135.
   Web of Science ®Google Scholar
• Traboulsi T, Ezzy M, El Gleason JL, Mader S. 2017. Antiestrogens: structure-activity relationships and use in breast cancer treatment. J Mol Endocrinol. 58(1):R15–R31.
   PubMed Web of Science ®Google Scholar
• Troschel FM, Böhly N, Borrmann K, Braun T, Schwickert A, Kiesel L, Eich HT, Götte M, Greve B. 2018. miR-142-3p attenuates breast cancer stem cell characteristics and decreases radioresistance in vitro. Tumour Biol. 40(8):1010428318791887–1010428318791810.
   Google Scholar
• Ueno NT, Espinosa Fernandez JR, Cristofanilli M, Overmoyer B, Rea D, Berdichevski F, El-Shinawi M, Bellon J, Le-Petross HT, Lucci A, et al. 2018. International consensus on the clinical management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer research program 10th anniversary conference. J Cancer. 9(8):1437–1447.
   PubMed Web of Science ®Google Scholar
• Wang B, Li D, Filkowski J, Rodriguez-Juarez R, Storozynsky Q, Malach M, Carpenter E, Kovalchuk O. 2018. A dual role of miR-22 modulated by RelA/p65 in resensitizing fulvestrant-resistant breast cancer cells to fulvestrant by targeting FOXP1 and HDAC4 and constitutive acetylation of p53 at Lys382. Oncogenesis. 7(7):54.
   PubMedGoogle Scholar
• Wang B, Zheng J, Li R, Tian Y, Lin J, Liang Y, Sun Q, Xu A, Zheng R, Liu M, et al. 2019. Long noncoding RNA LINC02582 acts downstream of miR-200c to promote radioresistance through CHK1 in breast cancer cells. Cell Death Dis. 10(10):764.
   PubMedGoogle Scholar
• Wang J, Song Wang H, Juan Qian H. l. 2018. Biological effects of radiation on cancer cells. Mil Med Res. 5(1):20.
   PubMedGoogle Scholar
• Wang L, Huang X, Zheng X, Wang X, Li S, Zhang L, Yang Z, Xia Z. 2013. Enrichment of prostate cancer stem-like cells from human prostate cancer cell lines by culture in serum-free medium and chemoradiotherapy. Int J Biol Sci. 9(5):472–479.
   PubMed Web of Science ®Google Scholar
• Wang L, Yuan C, Lv K, Xie S, Fu P, Liu X, Chen Y, Qin C, Deng W, Hu W. 2013. Lin28 mediates radiation resistance of breast cancer cells via regulation of caspase, H2A.X and Let-7 signaling. PLoS One. 8(6):e67373.
   PubMed Web of Science ®Google Scholar
• Weaver BA. 2014. How Taxol/paclitaxel kills cancer cells. Mol Biol Cell. 25(18):2677–2681.
   PubMed Web of Science ®Google Scholar
• World Cancer Research Fund. 2020. Breast cancer statistics. [online] [Accessed 28 Apr 2020]. Available from: https://www.wcrf.org/dietandcancer/cancer-trends/breast-cancer-statistics.
   Google Scholar
• World Health Organization. 2020. Breast cancer [online]. [Accessed 28 Apr 2020]. Available from: https://www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en/#:∼:text=Breastcanceristhemost,allcancerdeathsamongwomen.
   Google Scholar
• Wu C, Guo E, Ming J, Sun W, Nie X, Sun L, Peng S, Luo M, Liu D, Zhang L, et al. 2020. Radiation-induced DNMT3B promotes radioresistance in nasopharyngeal carcinoma through methylation of p53 and p21. Mol Ther Oncolytics. 17:306–319.
   PubMed Web of Science ®Google Scholar
• Yamaguchi H, Chang S-S, Hsu J, Hung M-C. 2014. Signaling cross-talk in the resistance to HER family receptor targeted therapy. Oncogene. 33(9):1073–1081.
   PubMed Web of Science ®Google Scholar
• Yang B, Kuai F, Chen Z, Fu D, Liu J, Wu Y, Zhong J. 2020. miR-634 decreases the radioresistance of human breast cancer cells by targeting STAT3. Cancer Biother Radiopharm. 35(3):241–248.
   PubMed Web of Science ®Google Scholar
• Yi Z, Ma F, Liu B, Guan X, Li L, Li C, Qian H, Xu B. 2019. Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study. BMC Cancer. 19(1):442.
   PubMedGoogle Scholar
• Yu L, Yang Y, Hou J, Zhai C, Song Y, Zhang Z, Qiu L, Jia X. 2015. MicroRNA-144 affects radiotherapy sensitivity by promoting proliferation, migration and invasion of breast cancer cells. Oncol Rep. 34(4):1845–1852.
   PubMed Web of Science ®Google Scholar
• Yu X, Liu Y, Yin L, Peng Y, Peng Y, Gao Y, Yuan B, Zhu Q, Cao T, Xie B, et al. 2019. Radiation-promoted CDC6 protein stability contributes to radioresistance by regulating senescence and epithelial to mesenchymal transition. Oncogene. 38(4):549–563.
   PubMed Web of Science ®Google Scholar
• Zeng X, Kinsella TJ. 2010. BNIP3 is essential for mediating 6-thioguanine- and 5-fluorouracil-induced autophagy following DNA mismatch repair processing. Cell Res. 20(6):665–675.
   PubMed Web of Science ®Google Scholar
• Zhang P, Wang L, Rodriguez-Aguayo C, Yuan Y, Debeb BG, Chen D, Sun Y, You MJ, Liu Y, Dean DC, et al. 2014. miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13. Nat Commun. 5(1):5671.
   PubMedGoogle Scholar
• Zhang S, Wang B, Xiao H, Dong J, Li Y, Zhu C, Jin Y, Li H, Cui M, Fan S. 2020. LncRNA HOTAIR enhances breast cancer radioresistance through facilitating HSPA1A expression via sequestering miR-449b-5p. Thorac Cancer. 11(7):1801–1816.
   Web of Science ®Google Scholar
• Zhang X, Li Y, Wang D, Wei X. 2017. miR-22 suppresses tumorigenesis and improves radiosensitivity of breast cancer cells by targeting Sirt1. Biol Res. 50(1):27.
   PubMedGoogle Scholar
• Zou Z, Chang H, Li H, Wang S. 2017. Induction of reactive oxygen species: an emerging approach for cancer therapy. Apoptosis. 22(11):1321–1335.
   PubMed Web of Science ®Google Scholar
• Zurrida S, Bassi F, Arnone P, Martella S, Castillo A, Del, Martini RR, Semenkiw ME, Caldarella P. 2011. The changing face of mastectomy (from mutilation to aid to breast reconstruction). Int J Surg Oncol. 2011:980158.
   PubMedGoogle Scholar